All In Biotech

Drug Trial Radar · NCT05907122

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 256 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

256

Actual

Start

Jul 26, 2023

Primary completion

Mar 26, 2025

Study completion Oct 31, 2025

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.

Conditions

  • Melanoma

Interventions

  • ABP 206Drug

    ABP 206 will be given intravenously over a period of 30 minutes, every 4 weeks (Q4W) for a total of 12 months.

  • FDA-licensed NivolumabDrug

    FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.

  • EU-authorized NivolumabDrug

    FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Serum Concentration-time Curve from Time Zero to 28 Days (AUC0-28d)Time frame: Day 1 (Postdose) through Day 28
  2. Area Under the Serum Concentration-time Curve Over the Dosing Interval at Steady State (AUCtau_SS)Time frame: Week 17 through Week 21

Locations

76 sites in 22 countries. Site status is shown where the registry gives one.

  • Cancer and Blood Specialty clinic

    Long Beach, California

  • St. Vincent Frontier Cancer Center - Oncology

    Billings, Montana

  • Centro De Investigaciones Medicas Mar Del Plata (CIMMDP) - Rheumatology

    Mar Del Plata, Río Negro Province, Argentina

  • University Clinical Hospital Mostar - Clinic for Lung Diseases

    Mostar, Bosnia and Herzegovina

  • Clinical Center University of Sarajevo - Clinic of Oncology

    Sarajevo, Kanton Sarajevo, Bosnia and Herzegovina

  • University Clinical Centre of the Republic of Srpska - Gastroenterology

    Banja Luka, Republika Srpska, Bosnia and Herzegovina

  • University Clinical Center Tuzla - Oncology, Hematology and Radio

    Tuzla, Tuzlanski Kanton, Bosnia and Herzegovina

  • Cantonal hospital Zenica - Oncology

    Zenica, Zeničko-dobojski Kanton, Bosnia and Herzegovina

  • Faculdade de Medicina de Sao Jose do Rio Preto-SP (FAMERP) - Hospital de Base (HB) - Oncology

    São Paulo, Brazil

  • ATO Oncologia

    Fortaleza, Ceará, Brazil

  • Hospital Sao Rafael

    Salvador, Estado de Bahia, Brazil

  • Hospital Sirio Libanes - Brasilia - Oncology

    Brasília, Federal District, Brazil

  • Cto Centro de Tratamento Oncologico Ltda

    Belém, Pará, Brazil

  • Instituto de Oncologia do Parana

    Curitiba, Paraná, Brazil

  • PUCRS - Hospital Sao Lucas - Uniao Brasileira de Educacao e Assistence

    Porto Alegre, Rio Grande do Sul, Brazil

  • CEPON - Centro de Pesquisas Oncológicas

    Florianópolis, Santa Catarina, Brazil

  • Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor

    Barretos, São Paulo, Brazil

  • Oncocentro Apys

    Valparaíso, Valparaiso, Chile

  • Klinicki bolnicki centar "Sestre milosrdnice" - Pediatrics

    Grad Zagreb, City of Zagreb, Croatia

  • University Hospital Centre Zagreb - Oncology department

    Zagreb, City of Zagreb, Croatia

  • LTD "Israel-Georgian Medical Research Clinic Healthycore"

    Tbilisi, Georgia

  • JSC "K.Eristavi National Center of Experimental and Clinical Surgery"

    Tbilisi, Georgia

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Italy

  • Istituto Dermopatico dell'Immacolata (IDI) - IRCCS - Oncologia

    Roma, Italy

  • Policlinico Santa Maria alle Scotte, Azienda Ospedaliero Universitaria Senese - Immunoterapia Oncolo

    Siena, Italy

  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.R.L

    Meldola, Forli, Italy

  • Kumamoto University Hospital - Dermatology

    Kumamoto, Japan

  • Niigata Cancer Center Hospital - Dermatology

    Niigata, Japan

  • Nagoya City University Hospital - Dermatology

    Nagoya, Aiti [Aichi], Japan

  • Sapporo Medical University Hospital

    Sapporo, Hokkaidô [Hokkaido], Japan

  • National Hospital Organization Kagoshima Medical Center - Haematology

    Kagoshima, Kagosima [Kagoshima], Japan

  • Osaka International Cancer Institute - Dermatological Oncology

    Osaka, Ôsaka [Osaka], Japan

  • Shizuoka Cancer Center - Dermatology

    Kōtoku, Tôkyô [Tokyo], Japan

  • Keio University Hospital - Dermatology

    Shinjuku-ku, Tôkyô [Tokyo], Japan

  • National Cancer Institute - Conservative Tumour Therapy

    Vilnius, Vilnius County, Lithuania

  • Hospital Pulau Pinang - Rheumatology

    Pulau Pinang, Pahang, Malaysia

  • Hospital Umum Sarawak

    Kuching, Sarawak, Malaysia

  • National Cancer Institute - Radiotherapy and Oncology

    Putrajaya, Selangor, Malaysia

  • Hospital Universiti Sains Malaysia

    Kubang Kerian, Terengganu, Malaysia

  • Hospital Kuala Lumpur - Surgery

    Kuala Lumpur, Wilayah Persekutuan Kuala Lump, Malaysia

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.